{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:16:56Z","timestamp":1788315416592,"version":"build-2803163510"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zoi250534-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Trimodal therapy (TMT) is included as an alternative to radical cystectomy (RC) for definitive management of muscle-invasive bladder cancer (MIBC) in current clinical guidelines. Moreover, a 2023 retrospective analysis reported similar oncologic outcomes between these treatments among patients deemed fit for RC. Data regarding the comparative value of these treatments are lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the comparative cost-effectiveness of TMT and RC for treatment of MIBC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This economic evaluation compared cost-effectiveness of treatments using a health transition state microsimulation model of patients with bladder cancer treated between 2005 and 2017 with 5- and 10-year horizons from a Medicare perspective. Model probabilities were informed by multicenter retrospective analyses published in 2023 comparing TMT with RC. The index patient was aged 71 years, with clinical stage T2-4aN0M0 MIBC, solitary tumor smaller than 7 cm, no or unilateral hydronephrosis, adequate bladder function, and lack of multifocal or extensive carcinoma in situ. Patients unfit for RC, radiation, or cisplatin-based chemotherapy were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>TMT and RC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-8\">\n                    <jats:title>Main Outcome and Measures<\/jats:title>\n                    <jats:p>Primary outcomes included effectiveness measured in quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER) using a willingness-to-pay threshold of $100\u202f000 per QALY. Sensitivity analyses were performed to assess the robustness of the model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For the index patient, at 5 years, the average cost was $30\u202f525 higher for TMT than RC. Average QALYs were 3.87 and 3.94 for RC and TMT, respectively. As such, TMT was not cost-effective at 5-year (ICER, $464\u202f291 per QALY) or 10-year (ICER, $308\u202f638 per QALY) time horizons. On 1-way sensitivity analyses, TMT would become cost-effective if (1) TMT costs were less than $17\u202f605; or (2) TMT resulted in an 11.6% improvement in metastasis-free survival relative to RC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zoi250534-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this economic evaluation study of TMT and RC for treatment of MIBC, TMT was associated with improved quality of life but was not cost-effective relative to RC at 5 and 10 years given higher treatment costs. These findings highlight the importance of developing policy initiatives that help reduce TMT costs and of providing patients with accurate expectations of long-term toxic effects to help guide preference-sensitive care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.17056","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:31:14Z","timestamp":1750678274000},"page":"e2517056","source":"Crossref","is-referenced-by-count":7,"title":["Cost-Effectiveness of Trimodal Therapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Daniel D.","family":"Joyce","sequence":"first","affiliation":[{"name":"Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Wymer","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Graves","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Boorjian","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Raza","family":"Khaki","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Oncology, Stanford University, Stanford, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann C.","family":"Raldow","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Williams","sequence":"additional","affiliation":[{"name":"Division of Urology, Department of Surgery, The University of Texas Medical Branch, Galveston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela B.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Urology, University of North Carolina at Chapel Hill"},{"name":"Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidit","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Urology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"issue":"3","key":"zoi250534r1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6 Pt 1","key":"zoi250534r2","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"issue":"10139","key":"zoi250534r3","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial.","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"zoi250534r5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline.","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"8","key":"zoi250534r7","doi-asserted-by":"publisher","first-page":"246.e7","DOI":"10.1016\/j.urolonc.2024.03.009","article-title":"Natural history and health care burden of non-curative treatment for muscle-invasive bladder cancer.","volume":"42","author":"Herzberg","year":"2024","journal-title":"Urol Oncol"},{"issue":"4","key":"zoi250534r8","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.juro.2010.06.007","article-title":"Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series.","volume":"184","author":"Stimson","year":"2010","journal-title":"J Urol"},{"issue":"5","key":"zoi250534r9","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE\u2014a randomised feasibility study of selective bladder preservation versus radical cystectomy.","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"issue":"6","key":"zoi250534r10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis.","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi250534r11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.urology.2006.03.062","article-title":"Clinical model of lifetime cost of treating bladder cancer and associated complications.","volume":"68","author":"Avritscher","year":"2006","journal-title":"Urology"},{"issue":"4","key":"zoi250534r12","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.euo.2019.01.015","article-title":"The cost to Medicare of bladder cancer care.","volume":"3","author":"Sloan","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"18","key":"zoi250534r13","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/BF03262330","article-title":"The health economics of bladder cancer: a comprehensive review of the published literature.","volume":"21","author":"Botteman","year":"2003","journal-title":"Pharmacoeconomics"},{"issue":"22","key":"zoi250534r14","doi-asserted-by":"publisher","first-page":"8491","DOI":"10.1002\/cam4.3478","article-title":"Trimodal therapy in T2-4aN0M0 bladder cancer\u2013how to select the best candidate?","volume":"9","author":"Gofrit","year":"2020","journal-title":"Cancer Med"},{"issue":"4","key":"zoi250534r15","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.3390\/jcm12041560","article-title":"Combined modality bladder-sparing therapy for muscle-invasive bladder cancer: how (should) we do it? a narrative review.","volume":"12","author":"Leminski","year":"2023","journal-title":"J Clin Med"},{"issue":"4","key":"zoi250534r16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer.","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"17","key":"zoi250534r17","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"11","key":"zoi250534r18","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma.","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi250534r19","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/archinte.163.14.1637","article-title":"What is the price of life and why doesn\u2019t it increase at the rate of inflation?","volume":"163","author":"Ubel","year":"2003","journal-title":"Arch Intern Med"},{"issue":"4","key":"zoi250534r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216255","article-title":"Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: does the current quality of evidence justify definitive conclusions?","volume":"14","author":"Wettstein","year":"2019","journal-title":"PLoS One"},{"issue":"6","key":"zoi250534r21","doi-asserted-by":"publisher","first-page":"273.e1","DOI":"10.1016\/j.urolonc.2022.01.007","article-title":"Long term cost comparisons of radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer.","volume":"40","author":"Golla","year":"2022","journal-title":"Urol Oncol"},{"issue":"8","key":"zoi250534r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2019.1629","article-title":"Comparison of costs of radical cystectomy vs trimodal therapy for patients with localized muscle-invasive bladder cancer.","volume":"154","author":"Williams","year":"2019","journal-title":"JAMA Surg"},{"issue":"4","key":"zoi250534r23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/UPJ.0000000000000403","article-title":"Cost of bladder cancer care: a single-center comparison of radical cystectomy and trimodal therapy.","volume":"10","author":"Magee","year":"2023","journal-title":"Urol Pract"},{"issue":"6","key":"zoi250534r24","doi-asserted-by":"publisher","first-page":"189","DOI":"10.5489\/cuaj.7430","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Canadian cost-effectiveness analysis.","volume":"16","author":"Kool","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"4","key":"zoi250534r25","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.5489\/cuaj.7453","article-title":"Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: a Markov microsimulation model.","volume":"16","author":"Magee","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"zoi250534r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110038","article-title":"Quality of life after definitive treatment for bladder cancer: a systematic review and meta-analysis.","volume":"190","author":"Francolini","year":"2024","journal-title":"Radiother Oncol"},{"issue":"11","key":"zoi250534r27","doi-asserted-by":"publisher","first-page":"456.e7","DOI":"10.1016\/j.urolonc.2023.07.005","article-title":"Assessing utilities for muscle-invasive bladder cancer-related health states.","volume":"41","author":"Chaballout","year":"2023","journal-title":"Urol Oncol"},{"issue":"1","key":"zoi250534r28","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1080\/13696998.2024.2382639","article-title":"An assessment of the direct and indirect costs of bladder cancer preceding and following a cystectomy: a real-world evidence study.","volume":"27","author":"Tkacz","year":"2024","journal-title":"J Med Econ"},{"issue":"10","key":"zoi250534r29","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer.","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"zoi250534r4","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology for bladder cancer version 4.2024. Accessed September 20, 2024. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1417"},{"key":"zoi250534r6","unstructured":"European Association of Urology. EAU Guidelines 2023. Accessed October 7, 2024. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2023.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2835469\/joyce_2025_oi_250534_1749744080.78586.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:31:15Z","timestamp":1750678275000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2835469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,23]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.17056","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,23]]}}}